alumis logo.png
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
April 30, 2024 08:00 ET | Alumis Inc
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
alumis logo.png
Alumis to Participate in the 2024 Leerink Partners Global Biopharma Conference
March 11, 2024 09:00 ET | Alumis Inc
SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of...
alumis logo.png
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
March 09, 2024 12:00 ET | Alumis Inc
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024.
alumis logo.png
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
March 06, 2024 08:00 ET | Alumis Inc
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors –      – Proceeds will support ongoing comprehensive mid to...
alumis logo.png
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
March 01, 2024 08:00 ET | Alumis Inc
– A-005 is a potential first-in-class, brain penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Data support planned Phase 1 clinical trial on track to...